Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in neoadjuvant hepatocellular carcinoma
NCT04425226Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Renji Hospital. Primary endpoints: Recurrence-Free Survival at 4 years and Objective Response Rate at 1 year. Status: unknown.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04425226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425226.